Ralph Neumüller

ICYMI in @CD_AACR: Zongertinib (BI 1810631), an Irreversible #HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, @Ralph_A_N, and colleagues doi.org/10.1158/2159-8… @Boehringer

🫁 Pralsetinib in RET+ NSCLC: ARROW final. ORR 78% (naïve) vs 63% (post–platinum) Median OS 44.3 mo Grade ≥3 AEs: anemia 21%, HTN 15%, neutropenia 13% Durable activity across lines in RET fusion+ NSCLC. 📖 @JCOPO_ASCO DOI 👉🏻 doi.org/10.1200/JCO-25… #CánCare #NSCLC #lcsm #RET #TargetedTherapy

Happy to share our pre-print

Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D | Journal of the American Chemical Society pubs.acs.org/doi/abs/10.102…

From the January issue: Zongertinib (BI 1810631), an Irreversible #HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers brnw.ch/21wQt3N By Birgit Wilding, @Ralph_A_N, and colleagues @Boehringer

Er ist da!! Der Soundtrack zu meinem neuen Roman "Das zweigeteilte All": "Traurige Maschinen" von und mit Kommando Elefant. Check out the Video. Wie im Buch steht Mensch-Maschine Interaktion im Fokus.😉 youtube.com/watch?v=tFC42p…

Happy to see our paper in print @CD_AACR Check it out! Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers aacrjournals.org/cancerdiscover…

@NatureBiotech @EllingUlrich @IMBA_Vienna Congratulations! This is awesome

Next-level CRISPR screening: New method for identifying cancer’s Achilles’ heels #NBTintheNews via @IMBA_Vienna oeaw.ac.at/imba/research-…

CRISPR-StAR enables high-resolution genetic screening in complex in vivo models go.nature.com/4giANvD

Concurrent with #WCLC24 Presidential Symposium: Zongertinib (BI 1810631) an Irreversible #HER2 TKI Spares EGFR Signaling & Improves Therapeutic Response in Preclinical Models & Patients with HER2-driven Cancers. Birgit Wilding,et al. bit.ly/3B6gKRj @Ralph_A_N @Boehringer

#NEWS: The results of our research on targeting mutated HER2, a protein regulating cell growth, have been published in @CD_AACR. Annually, more than 40,000 people are diagnosed with HER2-mutated non-small cell lung cancer. Learn more here: bit.ly/3zbFJlG

Check out our new paper in Cancer Discovery @CD_AACR. Targeting mutated #HER2 with a novel TKI in NSCLC and other HER2-driven cancers. aacrjournals.org/cancerdiscover…

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC @IASLC #WCLC24 #lcsm onclive.com/view/zongertin…

Concurrent with #WCLC24 Presidential Symposium: Zongertinib (BI 1810631) an Irreversible #HER2 TKI Spares EGFR Signaling & Improves Therapeutic Response in Preclinical Models & Patients with HER2-driven Cancers. Birgit Wilding,et al. bit.ly/3Zc6gKl @Ralph_A_N @Boehringer

@maxbillmann @DepMapSanger @CancerDepMap @anna_koeferle @dekegelb @colmr @UniBonn @UniklinikBonn Cool stuff, congratulations! Sounds interesting from the X-summary! Thanks for sharing, looking forward to reading the paper.

Everything is better with #BaCoN!? True when predicting gene buffering from @DepMapSanger @CancerDepMap following a hypothesis similar to what was previously formulated @anna_koeferle @Ralph_A_N @dekegelb @colmr A 🧵 1/12 @UniBonn @UniklinikBonn biorxiv.org/content/10.110…

@ashleyruba_phd A fundamental reform of the academic labor market. Reliance of labs on PhD students (and post docs) seems 2b the root cause. If that doesn’t help: guided meditation in nearby forest.

@JSheltzer We switched to AID2 and ARTi… the highly interpretable results make the cell line engineering worth the effort.

What’s the best system for generating inducible CRISPR knockouts in a mouse xenograft? My lab hasn’t had great results with dox-Cas9 due to leaky expression and incomplete induction…

@JSheltzer One experiment will not be too informative given the multi-parameter optimization behind clinical compounds.

A genie gives you two new cancer drugs. One drug will receive FDA approval while the other will fail in clinical testing. The genie challenges you to identify the drug that will succeed in the future. You can perform one experiment on each drug - what experiment do you choose?

Where we are in the sci-fi movie timeline [📊 danmeth. com]

@mbeisen Not too much of a topic in industry:-)

So, we still talking about H-Indexes?